Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
6/3/2026, 12:00:00 AM
The New Drug Application (NDA) for Olipudase (奥莱泊肽), a GLP-1/GIP dual receptor agonist, was accepted for review by China's NMPA on June 3, 2026. Analysts estimate a >10% price impact due to the drug's significant market potential expected.
Korean Translation
GLP-1/GIP 이중 수용체 작용제인 올레포타이드(奥莱泊肽)의 신약 허가 신청(NDA)이 2026년 6월 3일 중국 NMPA에 접수될 것으로 예상됨. 분석가들은 해당 약물의 시장 잠재력에 따른 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Hanwha Corp (000880) · Trading Issue
Trading suspension for Hanwha Corp shares is scheduled to begin on 2026-07-30 in connection with the corporate spin-off, with trading expected to resume on 2026-08-25 upon relisting of Hanwha Corp and listing of the spun-off entity.
7/30/2026, 12:00:00 AM
Hanwha Corp (000880) · Trading Issue
Hanwha Corp confirmed a corporate spin-off creating Hanwha Machinery & Service Holdings (tentative name), separating the tech and life solutions businesses from the surviving Hanwha Corp, which will retain defense, energy, finance and related core businesses. The action also entails a scheduled trading suspension and distribution of new shares to existing holders.
7/30/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
The U.S. FDA's final decision on the New Drug Application (NDA) for the Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer is expected by the PDUFA date of July 23, 2026; this major binary event is expected to have a high price impact expected
7/23/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM